中文 | English
Return
Total: 9 , 1/1
Show Home Prev Next End page: GO
Author:(Yiran YUAN)

1.Generation of RNase L knockout cell lines by CRISPR/Cas system

Ruihua LI ; Hanjiang FU ; Yiran ZHONG ; Yuan SHEN ; Jie ZHU ; Xiaofei ZHENG

Military Medical Sciences 2015;(10):742-746

2.Effects of combination of tandospirone,mosapride and Bella ray on the levels of oxygen free radicals and inflammatory cytokines in patients with reflux esophagitis

Zonghan DU ; Yiran YUAN ; Jun LUO

Clinical Medicine of China 2017;33(11):1010-1013

3.Correlation analysis of frailty and health literacy in elderly patients with chronic cardiac insufficiency

Yinyin WU ; Yuan MA ; Junkai DOU ; Min JIAO ; Yiran WU ; Xiubin TAO

Journal of Shenyang Medical College 2024;26(1):18-24

4.Prognostic value of lymphovascular invasion for patients with upper tract urothelial carcinoma after radical nephroureterectomy

Yichu YUAN ; Jiwei HUANG ; Yonghui CHEN ; Jin ZHANG ; Qi CHEN ; Haige CHEN ; Yiran HUANG ; Wei XUE

Chinese Journal of Urology 2017;38(12):891-895

5.Impact of tumor architecture on prognosis of patients with upper tract urothelial carcinoma

Yichu YUAN ; Nan ZHANG ; Jiwei HUANG ; Jin ZHANG ; Yonghui CHEN ; Yiran HUANG ; Chuanjun DU ; Jimin CHEN ; Wei XUE

Chinese Journal of Urology 2020;41(5):334-340

6.Immune Mechanism of Tumor Cell Lysate Combined with IL-2 Preventing Melanoma and Inhibiting Tumor Growth

Yiran SI ; Jian YUE ; Zhaoyang LIU ; Mo LI ; Yuanyi ZHENG ; Xiaobing WANG ; Peng YUAN

Cancer Research on Prevention and Treatment 2021;48(2):115-120

7.Effect of subclinical epileptiform discharges on cognitive function in adult epilepsy

Xiaoyun YU ; Songyan LIU ; Libo WANG ; Jing ZHANG ; Xinxin LI ; Yiran WU ; Fuli WANG ; Xuetao YUAN

Chinese Journal of Neurology 2018;51(5):349-354

8.A family of neurofibromatosis type Ⅰ: a clinical feature and gene mutation analysis

Zhihui TANG ; Daoqi MEI ; Shiyue MEI ; Yuan WANG ; Guohong CHEN ; Yanli MA ; Yiran ZHAO

Chinese Journal of Neuromedicine 2021;20(8):787-792

9. Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival

Wen CAI ; Yichu YUAN ; Mingyang LI ; Wen KONG ; Baijun DONG ; Yonghui CHEN ; Jin ZHANG ; Wei XUE ; Yiran HUANG ; Lixin ZHOU ; Jiwei HUANG

Chinese Journal of Oncology 2018;40(5):384-389

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 9 , 1/1 Show Home Prev Next End page: GO